From Compliance to Capability: What 2025 Meant for Contract Labs
From PFAS to supply chain compliance, 2025 tested how contract laboratories really adapted
Advertisement
The Biotechnology and Life Science sector utilizes biological systems to create innovative healthcare, agricultural, and industrial products such as pharmaceuticals and gene therapies.
Advertisement
From PFAS to supply chain compliance, 2025 tested how contract laboratories really adapted
Biosimilars represent a promising opportunity to enhance healthcare affordability and accessibility by providing alternatives to costly biologic therapies.
The ability to differentiate structures of tissue or cell samples is enhanced through different histology stains.
Laboratories must perform sterility testing to ensure that products are contaminant free
Cell and gene therapy are similar fields of biomedical research aimed at treating genetic diseases and are often combined in treatment.
Introduction: The Challenge of Biologic Therapeutics Biologics—therapeutic products derived...
Advertisement
Advertisement